Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peripheral T-cell lymphoma not otherwise specified

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    43 result(s) found for: Peripheral T-cell lymphoma not otherwise specified. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-003983-28 Sponsor Protocol Number: SGN35-028 Start Date*: 2020-11-27
    Sponsor Name:SEAGEN INC.
    Full Title: A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma...
    Medical condition: - classic Hodgkin lymphoma (cHL) - Systemic anaplastic large cell lymphoma (sALCL) - CD30-expressing peripheral T cell lymphoma (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073478 Anaplastic large-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001412 Adult T-cell leukemia-lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065855 Extranodal NK/T-cell lymphoma, nasal type LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073481 Enteropathy-associated T-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022703 Intestinal T-cell lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061232 Lymphoproliferative disorder PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066957 Hepatosplenic T-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002449 Angioimmunoblastic T-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004234-33 Sponsor Protocol Number: PTCL-06 Start Date*: 2006-10-06
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Intensive chemo-immunotherapy as first-line treatment in adult patients with peripheral T-cell Lymphoma PTCL
    Medical condition: Non Hodgkin peripheral T-cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    6.1 10034623 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003982-17 Sponsor Protocol Number: SGN35-015 Start Date*: 2020-10-21
    Sponsor Name:SEATTLE GENETICS, INC.
    Full Title: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant...
    Medical condition: • Hodgkin lymphoma (HL) • CD30-expressing peripheral T-cell lymphoma (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073478 Anaplastic large-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001412 Adult T-cell leukemia-lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065855 Extranodal NK/T-cell lymphoma, nasal type LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073481 Enteropathy-associated T-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022703 Intestinal T-cell lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061232 Lymphoproliferative disorder PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066957 Hepatosplenic T-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002449 Angioimmunoblastic T-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003526-80 Sponsor Protocol Number: CLSG-PTCL-CHEPA Start Date*: 2021-12-16
    Sponsor Name:Kooperativní lymfomová skupina, z.s.
    Full Title: A Phase II Open Label Study of Brentuximab Vedotin in combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas.
    Medical condition: Peripheral T-cell lymphomas (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002450 Angioimmunoblastic T-cell lymphomas HLT
    20.0 100000004851 10001414 Adult T-cell lymphomas/leukaemias HLT
    20.0 100000004851 10022704 Intestinal T-cell lymphomas HLT
    20.0 100000004851 10034622 Peripheral T-cell lymphomas NEC HLT
    21.0 100000004864 10002451 Angioimmunoblastic T-cell lymphoma NOS LLT
    21.0 100000004864 10001415 Adult T-cell lymphoma/leukaemia NOS LLT
    21.1 100000004864 10076434 Hepatosplenic gamma-delta T-cell lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006229-23 Sponsor Protocol Number: PTCLS-IDE Start Date*: 2022-04-07
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas.
    Medical condition: peripheral T Cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10003622 ATLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004146-18 Sponsor Protocol Number: CCR3549 Start Date*: 2011-11-09
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre rando...
    Medical condition: T-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10001414 Adult T-cell lymphomas/leukaemias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-002336-74 Sponsor Protocol Number: SGN35-032 Start Date*: 2020-12-08
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression
    Medical condition: Non-sALCL PTCL and CD30 expression <10%
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022230-81 Sponsor Protocol Number: PDX-017 Start Date*: 2011-04-05
    Sponsor Name:Allos Therapeutics, Inc.
    Full Title: A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Fo...
    Medical condition: Patients with previously undiagnosed peripheral T-cell lymphoma who have achieved an objective response following initial treatment with CHOP-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) IE (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004516-51 Sponsor Protocol Number: GEN112 Start Date*: 2006-11-20
    Sponsor Name:Genmab A/S
    Full Title: A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement
    Medical condition: CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement
    Disease: Version SOC Term Classification Code Term Level
    8.1 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001580-68 Sponsor Protocol Number: Ro-CHOP_study Start Date*: 2013-06-10
    Sponsor Name:LYSARC
    Full Title: Phase 3 Multi-Center Randomized Study to Compare Efficacy and Safety of Romidepsin¬ CHOP (Ro-CHOP) versus CHOP in subjects with Previously Untreated Peripheral T-Cell Lymphoma.
    Medical condition: Peripheral T-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing) IT (Completed) DE (Completed) PT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006228-21 Sponsor Protocol Number: GPI-06-0002 Start Date*: 2007-05-10
    Sponsor Name:Gloucester Pharmaceuticals Inc.
    Full Title: A PHASE II, MULTICENTER, OPEN-LABEL TRIAL EVALUATING THE ACTIVITY AND TOLERABILITY OF ROMIDEPSIN (DEPSIPEPTIDE, FK228) IN PROGRESSIVE OR RELAPSED PERIPHERAL T-CELL LYMPHOMA FOLLOWING PRIOR SYSTEM...
    Medical condition: Progressive or relapsed Peripheral T-Cell Lymphoma (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FR (Completed) ES (Completed) SE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002811-29 Sponsor Protocol Number: PDX-008 Start Date*: 2006-11-10
    Sponsor Name:Allos Therapeutics, Inc.
    Full Title: A Multi-center Phase 2 Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-...
    Medical condition: Phase 2 Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003545-18 Sponsor Protocol Number: C14012 Start Date*: 2012-04-24
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripher...
    Medical condition: Relapsed or Refractory Peripheral T-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034629 Peripheral T-cell lymphoma unspecified stage III PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034628 Peripheral T-cell lymphoma unspecified stage II PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034627 Peripheral T-cell lymphoma unspecified stage I PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034626 Peripheral T-cell lymphoma unspecified refractory PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034625 Peripheral T-cell lymphoma unspecified recurrent PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034630 Peripheral T-cell lymphoma unspecified stage IV PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) PT (Completed) DE (Completed) HU (Completed) AT (Completed) GB (Completed) ES (Completed) DK (Completed) NL (Completed) BG (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005039-34 Sponsor Protocol Number: ASTX660-01 Start Date*: 2018-02-05
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
    Medical condition: Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinoma; cohort 2:Relapsed or refractory diffuse large B-cell ly...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10011677 Cutaneous T-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted) FR (Completed) HU (Completed) ES (Ongoing) BE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004380-31 Sponsor Protocol Number: CM-2013-01 Start Date*: 2015-01-22
    Sponsor Name:Cell Medica Inc.
    Full Title: A Phase 2 open label study to investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive extranodal NK/T-cell lymphoma (ENKTCL).
    Medical condition: Aggressive EBV positive extranodal NK/T-cell lymphoma (ENKTCL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005889-38 Sponsor Protocol Number: UCL/10/0411 Start Date*: 2012-08-29
    Sponsor Name:University College London
    Full Title: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
    Medical condition: Acute myeloid leukaemia Myelodysplastic syndromes Therapy related AML or MDS Philadelphia positive Chronic Myeloid Leukaemia Acute lymphoblastic leukaemia Non-Hodgkin's lymphoma (follicular lymphom...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066355 Treatment related acute myeloid leukaemia LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003622 ATLL LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-004879-46 Sponsor Protocol Number: RG_16-123 Start Date*: 2017-06-15
    Sponsor Name:University of Birmingham
    Full Title: AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)
    Medical condition: Relapsed and refractory T-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001413 Adult T-cell lymphoma/leukaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004630-29 Sponsor Protocol Number: FIL_VERT Start Date*: 2018-06-15
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A phase II, open label, multicenter trial of Venetoclax (ABT-199/GDC-0199) as single agent in patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PT...
    Medical condition: Patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal T-cell lymphomas of T-folli...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042980 T-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042979 T-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001012-32 Sponsor Protocol Number: GPI-04-0001 Start Date*: 2005-03-31
    Sponsor Name:Gloucester Pharmaceuticals Inc.
    Full Title: A single agent Phase II study of depsipeptide (FK228) in the treatment of Cutaneous T-cell lymphoma
    Medical condition: Cutaneous T-cell lymphoma (CTCL), (peripheral T-cell lymphoma unspecified NOS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005580-27 Sponsor Protocol Number: ONC-2011-005 Start Date*: 2013-04-06
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: MULTI-CENTER, PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING REDUCED INTENSITY CONDITIONING (RIC) REGIMEN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE,...
    Medical condition: Patients with lymphomas (any histology) relapsed after high dose chemotherapy and in complete remission or partial remission after the last CT line
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003908 B-cell small lymphocytic lymphoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020206 Hodgkin's disease PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 03:12:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA